ChinaBio^® Partnering Forum 2012 Program Overview

China is expected to have the largest number of patent filings of any country in 2011; there have been over 3,200 patents for novel molecules in China since the year 2000, growing at an average rate of 45% per year. Partnering activity in China continues to increase, with the value of Chinese assets rising sharply with upfront payments now reaching USD 100 million and more.

This panel of senior pharma executives will recount their experiences in China, citing both successful and not so successful approaches of doing partnerships in the world's number two pharmaceutical market.

Moderator:
Greg B. Scott – President and Founder, ChinaBio^® LLC

Panelists:

• Richard Connell, PhD – VP, Head of Asia Research, Pfizer
• Berthold Hinzen, PhD – Head, Global Business Development and Licensing, General Medicine, Bayer HealthCare Pharmaceuticals
• Greg Wiederrecht, PhD, CLP – VP and Head, External Scientific Affairs, Worldwide Licensing, Merck Research Laboratories
• Steve Q. Yang, PhD – VP, Head of R&D, Asia and Emerging Markets, AstraZeneca

2010 was the year pharma recognized the extent and value of early stage innovation in China. AstraZeneca, Merck, Novartis and others have developed significant collaborations with Chinese universities and institutes, and several co-development deals were signed with local biotechs with a deal value exceeding USD 60 million. John Oyler will lead panelists in an examination of the questions concerning finding assets in China, and case studies of partnerships between pharma and China's leading universities and research institutes.

Moderator:
John Oyler, MBA – CEO and Founder, BeiGene

Panelists:

• Li Wang, PhD – Associate Director, Strategic Partnering, Business Development, Cardiovascular and Gastrointestinal, AstraZeneca AB
• Eric Whitters, PhD – VP, R&D, Novartis Diagnostics
• Rui-Ping Xiao, PhD – Director, Institute of Molecular Medicine, Peking University
• Tony Zhang, PhD – VP, Global External R&D, Asia, Eli Lilly

This session will discuss how to maximize IP value and avoid pitfalls in the context of building a patent portfolio for innovative pharma. The speakers will provide an overview of how IP protection can work for your company, as well as how to build a valuable IP portfolio to attract investment and how to prevent the loss of IP assets. Use of USFDA Orange Book listing and the Hatch-Waxman Act will also be discussed in the pharma IP context.

Speakers:

• Esther H. Lim, JD – Founding Managing Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, Shanghai Office
• Ningling Wang, JD – Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, Shanghai Office

The speakers in this session will discuss the legal issues of acquiring products and technologies from institutions in the West. To develop innovative life science products, there is an increasing need for Chinese pharmaceutical companies to acquire technologies in early stage development from the West. Background information will be provided concerning the culture, customs and laws related to technology acquisition from Western institutions. In addition, the speakers will analyze the latest deal structures, including assessing early stage products and managing a collaborative relationship post-signature. How to conduct proper IP due diligence in the transaction and managing of the IP post-transaction will also be discussed.

Speakers:

• Julian Thurston – Partner (London), Morrison & Foerster
• Jie Zhou, PhD, JD – Partner (Palo Alto), Morrison & Foerster

In 2010, the promise of venture capital becoming the engine for the commercialization of innovative life science technologies in China finally became a reality, establishing several new records in the process: the largest single investment (USD 120 million), the highest total investment (over USD 1 billion), and the highest average investment to date (USD 17 million). The public markets for Chinese biopharmaceutical companies also provided significant liquidity for investors, with 33 IPOs providing nearly USD 6 billion in proceeds and market caps reaching over USD 1 billion.

Will VC continue to drive innovation and are the high market values sustainable? Or was 2010 an anomaly driven by government incentives and investors' need to put capital to work? Leading investors and fund managers discuss the future of life science VC/PE in China.

Moderator:
John Carroll – Editor in Chief, FierceBiotech

Panelists:

• Norman Chen, MBA – Partner, Fidelity Growth Partners Asia
• James Huang, MBA – Managing Partner, Vivo Ventures
• Amit Kakar, MD – Head, Healthcare Asia, Avenue Capital
• James Li, MD – Partner, KPCB

China's life science industry continues to grow, and more significant deals between Western and Chinese companies are taking shape. In this session, seasoned dealmakers will discuss important transactions of the last twelve months. Getting the deal done is a complex procedure that involves in-depth analyses of the status quo of both partners as well as the goals of the collaboration. The panel will take a behind-the-scenes look at the drivers, options and strategies it takes to form a successful partnership in R&D, manufacturing or commercialization.

Moderators:

• Ruediger Herrmann, PhD – Partner, WilmerHale
• Alicia Hong – Head of China Practice, WilmerHale

Panelists:

• David Chen, MD, MBA – Executive Vice President and COO, 3SBio
• Kevin Li, PhD – CSO, China Nuokang Bio-Pharmaceutical
• Pu Wang, MBA – Co-CEO, Head of China Office, Xin Tech (Bio Science) Ltd.
• Xin Wu – Head of Strategy and Business Development, Bayer Healthcare China
• Donald W. Wyatt, JD – Corporate Counsel for International Transactions, 3SBio

Business development and dealmaking depend on secure intellectual property assets for predictable technology flow, capital generation, and partnerships. IP policies in China create opportunities and risks to be realized and managed as this enormous and expanding marketplace matures. For Western companies this is still a major stepping-stone when considering partnerships with Chinese companies. In this session, representatives from big pharma will discuss their IP concerns in China. They will also give hands-on advice to Chinese companies on how to manage and secure IP rights to attract pharma, form strong partnerships, preserve value, and secure capital investment. Panelists will provide insights to existing and emerging IP issues for R&D, business development, capital investment, and government partnerships in China.

Moderator:
Alfred W. Zaher, JD – Partner, Blank Rome

Panelists:

• Tomas Landh, PhD – Director, Novo Nordisk
• Shawn Shiqing Li, JD, PhD – Blank Rome
• Martina Molsbergen – CEO, C14 Consulting Group
• Jianzhong (David) Shen, JD, PhD – Asia Regional IP Counsel, Eli Lilly
• Ming-Wei Wang, PhD – Center Director, The National Center for Drug Screening; Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Pharmaron has grown from a bootstrapped start-up in 2003 to become the number three CRO in China. With over 1,200 employees, the acquisition of Bridge Laboratories in Beijing, and a war chest including USD 40 million in venture capital from DCM, Legend and others, Pharmaron is now positioned to challenge the leading CROs in China.

Dr Boliang Lou, CEO and founder, has led Pharmaron from the beginning. Eric Pierce, publisher of the well respected industry publication, BioCentury, will explore how Dr Lou was able to sustain rapid growth in this dynamic and challenging market, and what he plans for the future at Pharmaron.

Boliang Lou, PhD – Chairman & CEO, Pharmaron

Interviewed by: Eric Pierce – Publisher, BioCentury

There are now over 160 programs in China providing funding for new drug development, offering from USD 150,000 to USD 10 million and more for each project. Much of the funding comes from the provincial and municipal levels and has only been available to Chinese domestic companies and academic organizations. Now, with the twelfth five-year plan and the Mega New Drug Development Program, this is beginning to change.

Hear CEOs describe how they successfully secured funding, and government officials define the types of plans available. Also hear how Western companies can access these funding programs by establishing JVs with US-run China-based companies.

Moderator:
Ian Wisenberg – Managing Director, ChinaBio^® Capital Partners

Panelists:

• Yuwen Liu – CEO, BioBay
• Huijun Zhou Ring, PhD – Founder and CEO, iDNA.com.cn
• Bai Xu, PhD – President and CEO, Suzhou Natong Nanobiotechnology
• Dan Zhang, MD, MPH – Chairman and CEO, Fountain Medical Development